Research Studies
Renal Disease Research Institute (RDRI) is a research entity affiliated with Dallas Nephrology Associates. For more than 50 years, Dallas Nephrology Associates has been caring for patients with kidney disease, hypertension, transplants and complicated electrolyte disorders. The Research Institute allows us to conduct clinical trials that will improve our future ability to treat kidney disease and give our patients the opportunity to receive cutting-edge therapy. At RDRI, there is significant ethical oversight of this entity through RDRI’s Board of Managers and Scientific Review Committee.
Choosing to participate in a study is an important personal decision. Are you interested in participating in a study? Talk with your doctor and family members or friends about deciding to join a study.
SPARX: Safety and efficacy of sparsentan for patients post kidney transplantation with IgAN or FSGS
Protocol #: TVTX-RE021-426
Indication: Cardiovascular Event Risk Reduction
GFR: ≥25
Principal Investigator: Bernard Fischbach, MD, CCRP
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204
DETAILS >
AZURE: Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event
Protocol Name: AZURE: Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event
Protocol #: D7960C00015
Indication: Cardiovascular Event Risk Reduction
GFR: ≥15
Principal Investigator: Ankit N. Mehta, MD, FASN
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246
ZENITH: Zilebesiran in Patients with HTN not Adequately Controlled and with either Established CVD or at High Risk for CVD
Protocol Name: ZENITH: Zilebesiran in Patients with HTN not Adequately Controlled and with either Established CVD or at High Risk for CVD
Protocol #: ALN-AGT01-008
Indication: HTN (Uncontrolled)
GFR: <60
Principal Investigator: Ankit N. Mehta, MD, FASN
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246
A study to evaluate the efficacy and safety of frexalimab, brivekimig, and rilzabrutinib in patients with primary FSGS or minimal change disease
Protocol Name: A study to evaluate the efficacy and safety of frexalimab, brivekimig, and rilzabrutinib in patients with primary FSGS or minimal change disease
Protocol #: ACT18064
Indication: Fabry Disease
GFR: ≥ 45
Principal Investigator: Ankit N. Mehta, MD, FASN
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204
Observational Study of Safety and Effectiveness of Elfabrio in Fabry Patients
Protocol Name: Observational Study of Safety and Effectiveness of Elfabrio in Fabry Patients
Protocol #: CLI-06657AA1-10 (MODERN)
Indication: Fabry Disease
GFR: n/a
Principal Investigator: Ankit N. Mehta, MD, FASN
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204
CV Outcomes Study with CSL300 (Clazakizumab) in Adults with ESKD Undergoing Dialysis (POSIBIL6ESKD)
Protocol Name: CV Outcomes Study with CSL300 (Clazakizumab) in Adults with ESKD Undergoing Dialysis (POSIBIL6ESKD)
Protocol #: CSL300_2301 (POSIBIL6ESKD)
Indication: Dialysis
GFR: n/a
Principal Investigator: Bernard Fischbach, MD, CCRP
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246
AZD7760 Safety & PK in Adults with End-stage Kidney Disease on Hemodialysis with a Central Venous Catheter
Protocol Name: AZD7760 Safety & PK in Adults with End-stage Kidney Disease on Hemodialysis with a Central Venous Catheter
Protocol #: D7480C00001 PEAK
Indication: Dialysis
GFR: n/a
Principal Investigator: Kim M. Rice, MD
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Protocol Name: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Protocol #: M25-147 ANCHOR
Indication: Autosomal Dominant Polycystic Kidney Disease
GFR: ≥30
Principal Investigator: Michael R. Wiederkehr, MD
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246
Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
Protocol Name: Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
Protocol #: MZE829-201
Indication:APOL1-Mediated Proteinuric Kidney Disease
GFR: ≥25
Principal Investigator: Tapan J. Patel, MD, FACP, FASN, FNKF
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246
ASSESS: Double-blind, placebo-controlled, Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome
Protocol Name: ASSESS: Double-blind, placebo-controlled, Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome
Protocol #: 22419
Indication: Alport Syndrome
GFR: ≥45
Principal Investigator: Ankit Mehta, MD
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246
Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With ANCA-associated Vasculitis
Protocol Name: Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With ANCA-associated Vasculitis
Protocol #: 20220159
Indication: ANCA associated Vasculitis
GFR: ≥15
Principal Investigator: Ankit Mehta, MD
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin in Participants with Chronic Kidney Disease and High Blood Pressure
Protocol Name: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin in Participants with Chronic Kidney Disease and High Blood Pressure
Protocol #: D6972C00002
Indication: CKD & HTN
GFR: 30-75
Principal Investigator: Ankit Mehta, MD
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants with APOL1-Mediated Kidney Disease
Protocol Name: Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants with APOL1-Mediated Kidney Disease
Protocol #: D6800C00005
Indication: APOL1-Mediated Proteinuric Kidney Disease
GFR: ≥ 25
Principal Investigator: Akinwande Akinfolarin
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246
Does aldosterone synthase inhibition prevent kidney disease progression, heart failure or cardiovascular death?
Protocol Name: Does aldosterone synthase inhibition prevent kidney disease progression, heart failure or cardiovascular death?
Protocol #: EASi-Kidney
Indication: CKD
GFR: 20-90
Phase 2b Open-label Study of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease
Protocol Name: Phase 2b Open-label Study of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease
Protocol #: VX24-147-202
Indication: APOL1-Mediated Proteinuric Kidney Disease
GFR: ≥25 to ≤75
Principal Investigator: Bernard Fischbach, MD
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246
Efficacy and safety of extended TARPEYO® treatment >9 months in adult patients with primary IgA nephropathy
Protocol Name: Efficacy and safety of extended TARPEYO® treatment >9 months in adult patients with primary IgA nephropathy
Protocol #: Nef-403 (NefXtend)
Indication: IgA Nephropathy
Expanding and Promoting Alternative Care and Knowledge in Decision-Making: The ExPAND Study
Protocol Name: Expanding and Promoting Alternative Care and Knowledge in Decision-Making: The ExPAND Study (Improving Shared Decision-Making and Access to Non-Dialytic Treatment for People with Kidney Disease)
Protocol #: PCORI ExPAND
Indication: Late Stage CKD
GFR: <20
Observational Study Protocol – Fabry Disease Registry
Protocol Name: Observational Study Protocol – Fabry Disease Registry
Protocol #: DIREGC07006
Indication: Fabry Disease
Principal Investigator: Ankit Mehta, MD
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease (Vertex)
Protocol Name: Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease
Protocol #: VX21-147-301
Indication: APOL1-Mediated Proteinuric Kidney Disease
Primary Investigator: Bernard Fischbach, MD
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246